Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)
NCT ID: NCT02382991
Last Updated: 2019-10-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2015-03-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of the study is to evaluate the effect of the 3C60 knee, a microprocessor-controlled knee joint for external leg prosthesis, on the reduction in the risk of falling after three months in moderately active persons with leg amputation above knee or knee disarticulation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Correlations Between Different Walk Tests in Patients With Transfemoral Amputees
NCT02766387
Effects of Microprocessor-controlled Knee Joints on Community Outcomes
NCT04112901
Evaluation of a Neural-Controlled Powered Prosthesis Across Diverse Real-World Tasks
NCT07204912
C-Leg 3 and C-Leg 4 Study in Transfemoral Amputees
NCT02765035
Early Rehabilitation After Transfemoral Amputation in Moderately Active Patients
NCT06045468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After the trial with the 3C60 knee, the patient will again be fitted with his/her non microprocessor controlled knee joint (NMPK) and will be required to undergo one rehabilitation session to regain his/her walking abilities.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NMPK-3C60
D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
3C60-NMPK
3 months with 3C60 - 10 days wash out - 1 month with NMPK
3C60-NMPK
D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of "wash out". D1 + 30 days: evaluation with the non-microprocessor knee.
NMPK-3C60
1 month with NMPK - 3 months with 3C60
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3C60-NMPK
3 months with 3C60 - 10 days wash out - 1 month with NMPK
NMPK-3C60
1 month with NMPK - 3 months with 3C60
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person who are currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee
* Person with a high risk of falling, which is defined as a TGUG test score of more than 19 seconds
* Person who moves around within buildings other than one's residence, such as moving around other people's homes, other private buildings, community and private or public buildings and enclosed areas, moving throughout all parts of buildings and enclosed areas, between floors, inside, outside and around buildings, both public and private
* Person who moves around outside the home and other buildings, such as walking and moving around close to or far from one's home and other buildings, without the use of transportation, public or private, such as walking for short or long distances around a town or village, walking or moving down streets in the neighbourhood, town, village or city; moving between cities and further distances, without using transportation
* Person with a daily walking distance greater than 300 m
Exclusion Criteria
* Persons under 18 years of age
* Persons who weigh more than 125 kg
* Pregnant women
* Persons in an emergency situation
* Persons who cannot personally provide their consent
* Persons who are not available to follow the entire study protocol
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otto Bock France SNC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerard Chiesa, Physician
Role: PRINCIPAL_INVESTIGATOR
Institut Robert Merle d'Aubigné - 2 rue du Parc 94460 Valenton - France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sonderkrankenanstalt Zicksee
Sankt Andrä am Zicksee, , Austria
CRMPR "Les Herbiers"
Bois-Guillaume, , France
Hôpital d'instruction des Armées Percy
Clamart, , France
Centre Hospitalier de Cornouaille Concarneau
Concarneau, , France
Centre de réadaptation de Coubert
Coubert, , France
CHU de Grenoble Hôpital Sud
Échirolles, , France
Clinique Chantecler
Marseille, , France
Institut Régional de Médecine Physique et de Réadaptation
Nancy, , France
Institut National des Invalides
Paris, , France
Hôpital Léopold Belan
Paris, , France
Pôle Saint-Hélier
Rennes, , France
Hôpital privé de l'Est Lyonnais
Saint-Priest, , France
Centre l'Adapt Thionis
Thionville, , France
Institut Robert Merle d'Aubigné
Valenton, , France
Universitätsmedizin Göttingen
Göttingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schoppen T, Boonstra A, Groothoff JW, de Vries J, Goeken LN, Eisma WH. The Timed "up and go" test: reliability and validity in persons with unilateral lower limb amputation. Arch Phys Med Rehabil. 1999 Jul;80(7):825-8. doi: 10.1016/s0003-9993(99)90234-4.
Dite W, Connor HJ, Curtis HC. Clinical identification of multiple fall risk early after unilateral transtibial amputation. Arch Phys Med Rehabil. 2007 Jan;88(1):109-14. doi: 10.1016/j.apmr.2006.10.015.
Franchignoni F, Orlandini D, Ferriero G, Moscato TA. Reliability, validity, and responsiveness of the locomotor capabilities index in adults with lower-limb amputation undergoing prosthetic training. Arch Phys Med Rehabil. 2004 May;85(5):743-8. doi: 10.1016/j.apmr.2003.06.010.
Gauthier-Gagnon C, Grise MC, Potvin D. Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation. Arch Phys Med Rehabil. 1999 Jun;80(6):706-13. doi: 10.1016/s0003-9993(99)90177-6.
Burnfield JM, Eberly VJ, Gronely JK, Perry J, Yule WJ, Mulroy SJ. Impact of stance phase microprocessor-controlled knee prosthesis on ramp negotiation and community walking function in K2 level transfemoral amputees. Prosthet Orthot Int. 2012 Mar;36(1):95-104. doi: 10.1177/0309364611431611. Epub 2012 Jan 5.
Gauthier-Gagnon, C, grisé, MCL, Lepage Y. The Locomotor Capabilities Index : Content validity. J rehabil OutcomesMeas 2(4) : 40-46, 1998.
Gauthier-Gagnon, C, Grisé, MCL, Potvin, L. Predisposing factors related to prosthetic use by people with a transtibial and transfemoral amputation. J Prosthet Orthot 10: 99-109, 1998
Gauthier-Gagnon C, Grise MC. Prosthetic profile of the amputee questionnaire: validity and reliability. Arch Phys Med Rehabil. 1994 Dec;75(12):1309-14.
Grise MC, Gauthier-Gagnon C, Martineau GG. Prosthetic profile of people with lower extremity amputation: conception and design of a follow-up questionnaire. Arch Phys Med Rehabil. 1993 Aug;74(8):862-70. doi: 10.1016/0003-9993(93)90014-2.
Demers L, Weiss-Lambrou R, Ska B. Development of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST). Assist Technol. 1996;8(1):3-13. doi: 10.1080/10400435.1996.10132268.
Leplege A, Mesbah M, Marquis P. [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: the MOS SF-36 (version 1.1)]. Rev Epidemiol Sante Publique. 1995;43(4):371-9. French.
Leplège, A. (2001). Introduction, enjeux, définitions. In J. Coste et A. Leplège (Eds.), Mesure de la santé perceptuelle et de la qualité de vie : méthodes et applications (pp 15-36). Paris : Editions Estem
Ware JE, Snow KK, Kosinski M, Gandek B (1993). Health survey : manual and interpretation guide. Boston, Massachussets : The Health Institute, New England Medical Center, 1993
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
Loiret I, Paysant J, Martinet N, Andre JM. [Evaluation of amputees]. Ann Readapt Med Phys. 2005 Jul;48(6):307-16. doi: 10.1016/j.annrmp.2005.03.009. Epub 2005 Apr 15. French.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A00754-43
Identifier Type: REGISTRY
Identifier Source: secondary_id
20PT002-FR-01-0614
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.